Group 1 - Nearshore Protein (688137.SH) announced a share reduction plan by shareholders holding less than 5% of the company's shares [1] - Shareholder Heze Qiaobei plans to reduce holdings by up to 161,959 shares, representing a maximum of 0.2308% of total shares [2] - Shareholder Shanghai Pujin plans to reduce holdings by up to 263,158 shares, representing a maximum of 0.3750% of total shares [2] Group 2 - The reduction period for both shareholders is from July 14, 2025, to October 13, 2025 [2] - The shares to be reduced were acquired before the IPO, and the reason for the reduction is for their own operational development needs [2] - Nearshore Protein was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 29, 2022, with an initial offering price of 106.19 yuan per share [3] Group 3 - The total amount raised from the IPO was 1.8629825 billion yuan, with a net amount of 1.7421958 billion yuan after deducting issuance costs [3][4] - The company initially planned to raise 1.5 billion yuan, with the funds allocated for core diagnostic materials, innovative diagnostic reagent industrialization projects, research center construction, and working capital [4]

Core Viewpoint - The announcement details the share reduction plans of shareholders holding less than 5% of Suzhou Nearshore Protein Technology Co., Ltd, specifically Shanghai Qiaobei Investment Management Partnership and Shanghai Pujin Technology Development Partnership, due to their operational and funding needs [1][2]. Shareholder Holding Information - Shareholder Shanghai Qiaobei holds 795,292 shares, representing 1.1333% of the total share capital of the company [1][2]. - Shareholder Shanghai Pujin holds 263,158 shares, representing 0.3750% of the total share capital of the company [2][3]. Reduction Plan Details - Shanghai Qiaobei plans to reduce its holdings by up to 161,959 shares, which is a maximum of 0.2308% of the total shares, through centralized bidding and block trading from July 14, 2025, to October 13, 2025 [3]. - Shanghai Pujin plans to reduce its holdings by up to 263,158 shares, which is a maximum of 0.3750% of the total shares, through similar methods and during the same period [3]. Compliance and Commitments - The reduction plan is in compliance with the commitments made in the prospectus regarding advance notice of share reductions [2][4]. - The shareholders have committed to adhere to relevant laws and regulations regarding share transfers and reductions, ensuring that the reduction does not affect the company's governance structure or ongoing operations significantly [4].

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-027 苏州近岸蛋白质科技股份有限公司 关于持股 5%以下股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 股东上海乔贝投资管理合伙企业（有限合伙）－菏泽乔贝京煦创业投资合伙 企业（有限合伙）有限公司（以下简称"菏泽乔贝"）持有苏州近岸蛋白质科技 股份有限公司（以下简称"公司"）795,292 股股份，占公司总股本比例为 1.1333%； 股东上海普近科技发展合伙企业（有限合伙）（以下简称"上海普近"）持有公司 263,158 股股份，占公司总股本比例为 0.3750%。 减持计划的主要内容 1 | 股东名称 | 上海普近 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：5%以下股 ...

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-026 苏州近岸蛋白质科技股份有限公司 具 体 内 容 详 见 公 司 于 2024 年 9 月 28 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《苏州近岸蛋白质科技股份有限公司关于稳定股价措 施暨以集中竞价方式回购股份方案的公告》（公告编号：2024-041）。 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/30 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 7 7 | 年 | 月 | 27 | 日~2025 | 年 | 月 | 26 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激 ...

Core Insights - Nearshore Protein (688137) is focusing on protein tool innovation and applications, providing timely and high-quality products and services for innovative drug development companies and other life health application enterprises [1][2] - The company reported a revenue of 128 million yuan for the fiscal year 2024, a year-on-year decrease of 16.73%, and a net profit attributable to the parent company of -54.4163 million yuan, a significant decline of 523.68% [1] Group 1 - The company has increased investments in product quality improvement and business expansion to adapt to market changes and achieve high-quality development [1] - Nearshore Protein has made substantial progress in expanding its overseas market presence, establishing international professional teams in key markets such as the United States and Europe [2] - The global sales network now covers multiple major countries and regions, with a focus on core customer groups including international pharmaceutical companies, biotech firms, and research institutions [2] Group 2 - The company is enhancing the application of AI in the life sciences sector while advancing the industrialization of various synthetic biology projects, including collagen raw materials [2] - Nearshore Protein is actively seeking collaboration investments and acquisitions related to its main business to integrate upstream and downstream industry chain resources, enriching its industrial layout and creating a new industry ecosystem [2]

Core Points - The company, Suzhou Novoprotein Technology Co., Ltd., will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 30, 2025, from 16:00 to 17:00 [1] - The briefing will be conducted online via the Value Online platform, allowing for interactive communication with investors [1][2] - Investors can submit questions prior to the meeting through a designated website or by scanning a QR code [1] Meeting Details - Meeting Date and Time: June 30, 2025, from 16:00 to 17:00 [1] - Meeting Location: Value Online (www.ir-online.cn) [1] - Meeting Format: Online interactive session [1] Participants - Key attendees will include the Chairman and General Manager, Mr. Zhu Huaxing, the Vice General Manager and Board Secretary, Mr. Wang Duqiang, and the Chief Financial Officer, Mr. Zhang Dongye [1] Investor Participation - Investors can join the meeting through the provided website or by scanning a QR code on the day of the event [1] - Questions can be submitted before the meeting for the company to address during the session [1] Contact Information - Contact Department: Securities Affairs Department [1] - Phone: 021-50798028 [1] - Email: IR@novoprotein.com.cn [1] Additional Information - After the meeting, investors can access the details and main content of the performance briefing on the Value Online platform or via the Yidong app [1]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-025 苏州近岸蛋白质科技股份有限公司 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露了《2024 年年度报告》《2024 年年度报告摘要》及《2025 年第一季度报告》。为便于广大投资者更加全面深 入地了解公司经营业绩、发展战略等情况，公司定于 2025 年 06 月 30 日（星期 会议召开时间：2025 年 06 月 30 日（星期一）16:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 06 月 30 日 前 访 问 网 址 https://eseb.cn/1prL7NacKg8 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 一）16:00-17:00 在"价值在线"（www.ir-online.cn）举办苏州近岸蛋白质科 技股份有限公司 2024 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-023 苏州近岸蛋白质科技股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监 管指引第1号——规范运作》等相关规定，上述账户将专用于暂时闲置募集资金进行 现金管理的结算，不会用于存放非募集资金或用作其他用途。公司将在产品到期且 无后续使用计划时及时注销以上专户。 二、风险控制措施 1、公司将严格按照《上市公司募集资金监管规则》《上海证券交易所科创板上 市公司自律监管指引第1号——规范运作》《上海证券交易所科创板股票上市规则》 等有关规定办理相关现金管理业务。 2、公司按照决策、执行、监督职能相分离的原则建立健全现金管理的审批和执 行程序，有效开展和规范运行现金管理的投资产品购买事宜，确保资金安全。 3、公司将严格遵守审慎投资原则筛选投资对象,主要选择信誉好、规模大、有 能力保障资金安全的发行主体所发行的产品。 4、公司财务部相关人员将及时分析和跟踪投资产品的投向、项目进展情况，如 评估发现存在可能影响公司资金安全的风险因素，将及时采取相应保全措施,控制理 财风险。 本 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-022 苏州近岸蛋白质科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/30 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 7 月 26 | 年 | 27 | 日~2025 | 年 | 7 | 月 | 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 40.4337万股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.5762% | | | ...